Senti Bio Announces Second Quarter 2024 Results and Reviews Recent Corporate and Pipeline Highlights
Provided By GlobeNewswire
Last update: Aug 13, 2024
– Dose finding ongoing in Phase 1 clinical trial of SENTI-202 for the treatment of relapsed/refractory hematologic malignancies including AML –
– Commencement of $8 million grant award from CIRM for the clinical development of SENTI-202 –
Read more at globenewswire.comNASDAQ:SNTI (2/21/2025, 8:00:02 PM)
3.96
-0.03 (-0.75%)
Find more stocks in the Stock Screener
